PMID: 6107767Nov 29, 1980Paper

Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment

Lancet
D N SharpeB Long

Abstract

The acute haemodynamic effects of low doses of the oral converting-enzyme inhibitor, captopril, were studied in 18 patients with severe chronic heart failure. The effects of long-term therapy were also evaluated. Increasing doses (1 mg, 2.5 mg, 6.25 mg, 12.5 mg, and 25 mg) of captopril were given at 2 h intervals with haemodynamic monitoring. Graded haemodynamic improvement (increased stroke-volume index and reduced mean pulmonary capillary wedge pressure) was noted from 1 hand was closely associated with reduction of blood pressure. Maximal haemodynamic improvement for the group was seen at 6 h and 7 h after the 6.25 mg and 12.5 mg doses, when stroke-volume index had risen 35% and mean pulmonary capillary wedge pressure had fallen 40% from control. Captopril 12.5-50 mg every 8 h was continued long term but was withdrawn in 2 patients with symptomatic hypotension and 1 patient with altered taste. 4 patients died and 1 was noncompliant with therapy. At 3 months, 10 patients showed significant improvement in symptoms, treadmill-exercise duration, and echocardiographic indices of left-ventricular size and function. Repeat haemodynamic measurements were similar to optimum measurements obtained during the initial study.

References

Oct 20, 1979·Lancet·A B Atkinson, J I Robertson
Jul 7, 1977·The New England Journal of Medicine·J N Cohn, J A Franciosa
Sep 1, 1979·The American Journal of Cardiology·U ElkayamE H Sonnenblick
Dec 1, 1976·Circulation·K ChatterjeeA Norman
Jul 1, 1968·The American Journal of Cardiology·J GenestR Boucher
Jan 31, 1970·The Medical Journal of Australia·R Vandongen, R D Gordon
Nov 1, 1972·The American Journal of Cardiology·J A PattersonR M Gunnar
Jan 19, 1980·Lancet·P van BrummelenJ Thompson

❮ Previous
Next ❯

Citations

Jan 1, 1986·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·C Hall, B E Karlberg
Feb 1, 1990·Cardiovascular Drugs and Therapy·N Sharpe
Nov 1, 1981·Agents and Actions·K M Taylor, D N Sharpe
Dec 1, 1989·American Heart Journal·R A Scott, D B Barnett
Oct 1, 1988·Journal of Steroid Biochemistry·B WaeberH R Brunner
Jun 20, 1981·Lancet
Jun 13, 2001·Journal of the American College of Cardiology·M T JaberansariD M Yellon
Apr 9, 1983·British Medical Journal·P C Rubin, J L Reid
Nov 1, 1981·British Heart Journal·G L PierpontJ N Cohn
Apr 1, 1983·British Heart Journal·H J DargieJ I Robertson
Oct 1, 1985·British Heart Journal·B P McGrathC I Johnston
Feb 1, 1986·British Heart Journal·M RademakerC R Edwards
Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·H R BrunnerJ Biollaz
Apr 1, 1986·European Journal of Clinical Investigation·O B PaulsonJ Godtfredsen
Sep 1, 1990·International Journal of Cardiology·I S AnandP A Poole-Wilson
Apr 1, 1986·International Journal of Cardiology·H J GomezJ F Walker
May 5, 1999·Journal of Cardiovascular Pharmacology·J Cosín-AguilarE Marin-Huerta
Oct 1, 1981·European Journal of Clinical Investigation·J Giese, S Rasmussen
Oct 1, 1981·European Journal of Clinical Investigation·F BrivetJ Dormont
Oct 1, 1982·Australian and New Zealand Journal of Medicine·D N Sharpe, R Coxon
Dec 1, 1982·Journal of Clinical and Hospital Pharmacy·M J KendallM H Thomson
Nov 1, 1985·Clinical Cardiology·S G ChrysantJ R Konijeti
Dec 1, 1981·Drug Intelligence & Clinical Pharmacy·C Harris, G H Smith
Jan 1, 1982·British Journal of Clinical Pharmacology·T B Levine, J N Cohn

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.